keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/28509133/denosumab-for-treatment-of-immobilization-related-hypercalcemia-in-a-patient-with-end-stage-renal-disease
#1
Atsuko Uehara, Masahiko Yazawa, Atsumi Kawata, Rina Hachisuka, Yugo Shibagaki
The efficacy and safety of denosumab for the treatment of immobilization-related hypercalcemia in end-stage renal disease remain uncertain. We describe the case of a hemodialysis patient with immobilization-related hypercalcemia who was successfully treated with denosumab. A 79-year-old man admitted for hemodialysis after sustaining an acute kidney injury developed immobilization-related hypercalcemia due to the impairment resulting from an acute myocardial infarction, acute heart failure, and catheter-related bloodstream infection...
May 2017: CEN Case Reports
https://www.readbyqxmd.com/read/28500448/bone-loss-after-denosumab-only-partial-protection-with-zoledronate
#2
Ian R Reid, Anne M Horne, Borislav Mihov, Gregory D Gamble
A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD) in the spine increased 18.5% (P = 0.006), and total hip BMD by 6.9% (P = 0.03). Post-zoledronate BMDs were measured 18-23 months after treatment, and there were significant declines at each site (P spine = 0.043, P hip = 0.005). Spine BMD remained significantly above the pre-denosumab baseline (+9...
May 13, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28494404/treatment-and-pattern-of-bone-metastases-in-1094-patients-with-advanced-breast-cancer-results-from-the-prospective-german-tumour-registry-breast-cancer-cohort-study
#3
Jan Schröder, Thomas Fietz, Andreas Köhler, Volker Petersen, Hans Tesch, Lisa Spring, Annette Fleitz, Martina Jänicke, Norbert Marschner
A high proportion of patients with breast cancer develop bone metastases, yet data on routine treatment with bone-targeted agents (BTA) are rare. We report real-life outcome data of patients with breast cancer metastasised to the bone treated by office-based oncologists in Germany. The ongoing, prospective, multicentre, population-based cohort study Tumour Registry Breast Cancer (TMK) was started in 2007 in 140 centres across Germany. This interim analysis of 1094 patients with bone metastases revealed differences among the tumour subtypes: at start of first-line therapy, 36% of the patients with hormone receptor (HR)-positive and only 20% of the patients with HR-negative tumours presented with bone-only metastasis...
May 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28492856/treatment-of-low-bone-density-or-osteoporosis-to-prevent-fractures-in-men-and-women-a-clinical-practice-guideline-update-from-the-american-college-of-physicians
#4
Amir Qaseem, Mary Ann Forciea, Robert M McLean, Thomas D Denberg
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011...
May 9, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28485692/cost-effectiveness-of-denosumab-versus-zoledronic-acid-for-preventing-skeletal-related-events-in-the-czech-republic
#5
Joaquim Cristino, Jíndřich Finek, Petra Jandova, Martin Kolek, Bálint Pásztor, Christina Giannopoulou, Yi Qian, Tomas Brezina, Mickael Lothgren
AIMS: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor, denosumab, versus the intravenous bisphosphonate, zoledronic acid, for the prevention of skeletal-related events (SREs) in patients with prostate cancer, breast cancer, and other solid tumors (OST) in the Czech Republic. MATERIALS AND METHODS: A lifetime Markov model was developed to compare the effects of denosumab and zoledronic acid on costs (including drug costs and administration, patient management, SREs, and adverse events), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from a national payer perspective...
May 9, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28467663/screening-for-atypical-femur-fractures-using-extended-femur-scans-by-dxa
#6
Denise M van de Laarschot, Alexandra A A Smits, Sanne K C Buitendijk, Merel T Stegenga, M Carola Zillikens
Atypical femur fractures (AFFs) are a rare but serious complication associated with the use of antiresorptive drugs such as bisphosphonates. Assessment of incomplete AFFs on extended femur scans by Dual X-ray Absorptiometry (DXA) may prevent the development of complete fractures. The aim of this study was to evaluate the potential of extended femur scans by DXA as a screening tool for incomplete AFFs. From June 2014 until September 2016 extended femur scans were routinely performed in all consecutive patients undergoing DXA scanning who had used bisphosphonates or denosumab at any given moment in the previous year...
May 3, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28464481/correlation-of-mammographic-density-and-serum-calcium-levels-in-patients-with-primary-breast-cancer
#7
Carolin C Hack, Martin J Stoll, Sebastian M Jud, Katharina Heusinger, Werner Adler, Lothar Haeberle, Thomas Ganslandt, Felix Heindl, Rüdiger Schulz-Wendtland, Alexander Cavallaro, Michael Uder, Matthias W Beckmann, Peter A Fasching, Christian M Bayer
Percentage mammographic breast density (PMD) is one of the most important risk factors for breast cancer (BC). Calcium, vitamin D, bisphosphonates, and denosumab have been considered and partly confirmed as factors potentially influencing the risk of BC. This retrospective observational study investigated the association between serum calcium level and PMD. A total of 982 BC patients identified in the research database at the University Breast Center for Franconia with unilateral BC, calcium and albumin values, and mammogram at the time of first diagnosis were included...
May 2, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28462158/severe-hypophosphatemia-following-denosumab-administration-in-a-hemodialysis-patient-with-progressive-prostate-cancer
#8
Hiroshi Masuda, Kanya Kaga, Masahiko Inahara, Kazuhiro Araki, Satoko Kojima, Yukio Naya, Makoto Takano
In a 68-year-old man on maintenance hemodialysis (HD), severe anemia was detected. Bone marrow biopsy was performed for investigation of pancytopenia and pathological examination revealed adenocarcinoma of the prostate. Prostate specific antigen (PSA) was 574 ng/mL. After androgen deprivation therapy was initiated, PSA decreased to 13.7 ng/mL. But subsequent elevation of PSA and pain due to bone metastases were recognized. Denosumab (120 mg) was administered. Although improvement of bone pain was observed, severe hypocalcemia occurred...
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28458516/profile-of-romosozumab-and-its-potential-in-the-management-of-osteoporosis
#9
REVIEW
Sian Yik Lim, Marcy B Bolster
Increased understanding of bone biology has led to the discovery of several unique signaling pathways that regulate bone formation and resorption. The Wnt signaling pathway plays a significant role in skeletal development, adult skeletal homeostasis, and bone remodeling. Sclerostin is an inhibitor of the Wnt signaling pathway. Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect. Therefore, in the presence of romosozumab, the Wnt signaling pathway is activated leading to bone formation and bone mineral density gain...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28454732/fluvastatin-prevents-lung-adenocarcinoma-bone-metastasis-by-triggering-autophagy
#10
Zuozhang Yang, Zhenyi Su, Judy Park DeWitt, Lin Xie, Yongbin Chen, Xiaojuan Li, Lei Han, Dongqi Li, Junfeng Xia, Ya Zhang, Yihao Yang, Congguo Jin, Jing Zhang, Su Li, Kun Li, Zhiping Zhang, Xin Qu, Zewei He, Yanjin Chen, Yan Shen, Mingyan Ren, Zhongqin Yuan
Bone is one of the most preferred sites of metastasis in lung cancer. Currently, bisphosphonates and denosumab are major agents for controlling tumor-associated skeletal-related events (SREs). However, both bisphosphonates and denosumab significantly increase the risk for jaw osteonecrosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the most frequently prescribed cholesterol-lowering agents, have been reported to inhibit tumor progression and induce autophagy in cancer cells...
April 11, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28454368/anti-osteoclastic-agent-denosumab-for-a-giant-cell-tumor-of-the-bone-with-concurrent-paget-s-disease-a-case-report
#11
Takaaki Tanaka, John Slavin, Sue-Anne McLachlan, Peter Choong
Paget's disease of the bone may predispose the development of malignant bone tumors such as osteosarcoma. Giant cell tumor (GCT) as a consequence of Paget's disease is rare. Bone GCT is characterized by rapid growth, the destruction of bone, extension to the surrounding soft tissue and abnormal bone turnover caused by an abnormality of the receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) pathway. Denosumab is a RANK-RANKL inhibitor, which is used to treat osteoporosis and bone GCT. In the current study, a 60-year-old male presented with severe pain located between the right thigh and the knee...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28451704/-benign-tumours-and-tumour-like-lesions-of-the-bone-general-treatment-principles
#12
REVIEW
H Fritzsche, K-D Schaser, C Hofbauer
BACKGROUND: Benign bone lesions are much more common than malignant lesions. Some benign bone tumors have a characteristic and typical radiographic appearance, while others are more challenging. Therapy of benign bone tumors differs greatly. While the majority of benign bone tumors do not require surgical therapy, other specific lesions, e. g. aneurysmal bone cysts or giant cell tumors (GCT) of the bone require surgery due to their locally aggressive behavior. DIAGNOSTICS: The major challenge for the radiologist and/or pathologist is the differentiation between a benign and low-grade malignant lesion (e...
April 27, 2017: Der Orthopäde
https://www.readbyqxmd.com/read/28451403/successful-treatment-with-denosumab-in-a-patient-with-sacral-giant-cell-tumor-of-bone-refractory-to-combination-therapy-with-arterial-embolization-and-zoledronic-acid-a-case-report
#13
Shunji Nishimura, Kazuhiko Hashimoto, Akihiro Tan, Yukinobu Yagyu, Masao Akagi
Giant cell tumor of bone (GCTB) is commonly treated with surgery; however, surgery of GCTB in the sacrum may be challenging due to the associated risk. A conservative approach may be selective arterial embolization or zoledronic acid (ZOL) treatment; however, there are currently no studies investigating the efficacy of combining these two treatments. Denosumab may also be used; however, to the best of our knowledge, there are no reports of a stepwise approach for the use of all three treatments in a single patient...
March 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28449657/influence-of-subject-discontinuation-on-long-term-nonvertebral-fracture-rate-in-the-denosumab-freedom-extension-study
#14
Jonathan D Adachi, Henry G Bone, Nadia S Daizadeh, Paula Dakin, Socrates Papapoulos, Peyman Hadji, Chris Recknor, Michael A Bolognese, Andrea Wang, Celia J F Lin, Rachel B Wagman, Serge Ferrari
BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study. METHODS: To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not...
April 27, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28448754/clinical-evaluation-of-cost-efficacy-of-drugs-for-treatment-of-osteoporosis-a-meta-analysis
#15
Stewart G Albert, Supraja Reddy
OBJECTIVE: To assess the cost efficacy of available regimens for therapy of osteoporosis as defined as the cost time's number need to treat to prevent one fracture. PATIENTS AND METHODS: Existing meta-analyses were supplemented through electronic databases SCOPUS and PubMED between 2013 (a date overlapping the latest meta-analyses) and March 2016. Primary references included all randomized controlled trials of anti-osteoporotic drugs versus comparators using search terms "osteoporosis", "random" and "trial"...
April 27, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28445420/vitamin-d-and-calcium-are-required-during-denosumab-treatment-in-osteoporosis-with-rheumatoid-arthritis
#16
Yukio Nakamura, Takako Suzuki, Tomohiko Yoshida, Hideshi Yamazaki, Hiroyuki Kato
The aim of this 12-month retrospective study was to evaluate differences in the outcomes of denosumab alone or denosumab combined with vitamin D and calcium supplementation in patients having osteoporosis (OP) with rheumatoid arthritis (RA). Patients were divided into the denosumab monotherapy group (denosumab group, 22 cases) or denosumab plus vitamin D supplementation group (combination group, 21 cases). We measured serum bone alkaline phosphatase (BAP), N-terminal propeptide of type 1 collagen (P1NP), tartrate-resistant acid phosphatase (TRACP)-5b, and urinary N-terminal telopeptide of type-I collagen (NTX) at baseline, 1 week, and 1, 2, 4, 6, 8, and 12 months...
April 26, 2017: Nutrients
https://www.readbyqxmd.com/read/28441213/the-role-of-denosumab-in-the-modern-treatment-of-giant-cell-tumor-of-bone
#17
Patrick Thornley, Anthony Habib, Anthony Bozzo, Nathan Evaniew, Michelle Ghert
No abstract text is available yet for this article.
April 25, 2017: JBJS Reviews
https://www.readbyqxmd.com/read/28432640/osteoporosis-bone-mineral-density-and-ckd-mbd-treatment-considerations
#18
REVIEW
Jordi Bover, Lucía Bailone, Víctor López-Báez, Silvia Benito, Paola Ciceri, Andrea Galassi, Mario Cozzolino
Osteoporosis and chronic kidney disease (CKD) have both independently important potential impact on bone health. A significant number of patients with CKD stages 3a-5D have been shown to have low bone mineral density (BMD), leading to a strikingly elevated risk of fractures (mainly hip fractures) and higher associated morbidity and mortality. Mechanical properties of bone beyond age and menopausal status are additionally affected by intrinsic uremic factors. Therefore, we review in this article not only general concepts of osteoporosis and related consequences, but also the diagnostic and therapeutic implications of low BMD and bone fractures in CKD, beyond increased vascular calcification...
April 21, 2017: Journal of Nephrology
https://www.readbyqxmd.com/read/28429555/management-of-mineral-and-bone-disorders-in-renal-transplant-recipients
#19
Matthew J Damasiewicz, Peter R Ebeling
The management of post-transplantation bone disease is a complex problem that remains under-appreciated in clinical practice. In these patients, pre-existing metabolic bone disorder is further impacted by the use of immunosuppressive medications (glucocorticoids and calcineurin-inhibitors), variable post-transplantation renal allograft function and post-transplantation diabetes mellitus. The treatment of post-transplantation bone loss should begin pre-transplantation. All patients active on transplant waiting lists should be screened for bone disease...
March 2017: Nephrology
https://www.readbyqxmd.com/read/28429148/an-observational-time-and-motion-study-of-denosumab-subcutaneous-injection-and-zoledronic-acid-intravenous-infusion-in-patients-with-metastatic-bone-disease-results-from-three-european-countries
#20
Jean-Jacques Body, Francesca Gatta, Erwin De Cock, Sunning Tao, Persefoni Kritikou, Pauline Wimberger, Jeroen Mebis, Marc Peeters, Paolo Pedrazzoli, Augusto Caraceni, Vincenzo Adamo, Guy Hechmati
PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy...
April 21, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"